As you would expect, given how the last minutes in the US trading influences Asia – we opened lower. The Nikkei did attempt a small recovery just after the opening, but this was not to last and in-fact the selling
January 30, 2018
Florida-based investment manager Polen Capital is bullish on Regeneron Pharmaceuticals Inc (Nasdaq:REGN), a New York-based biotech company with six FDA-approved medicines and numerous product candidates in a range of diseases, including asthma, pain, cancer and infectious diseases. Polen Capital discussed Regeneron Pharmaceuticals and